naa a22 4500 510779492 CHVBK 20180411083242.0 cr unu---uuuuu 180411e20130601xx s 000 0 eng 10.1007/s11892-013-0377-9 doi (NATIONALLICENCE)springer-10.1007/s11892-013-0377-9 The Place of GLP-1-Based Therapy in Diabetes Management: Differences Between DPP-4 Inhibitors and GLP-1 Receptor Agonists [Elektronische Daten] [Dara Eckerle Mize, Marzieh Salehi] Type 2 diabetes is a progressive disease characterized by the need for additional antidiabetic agents overtime to maintain a stable level of glycemic control. The discovery of the glucagon like peptide 1, 1 of the 2 major incretins, was pivotal to the development of novel therapies, which can be used in individuals with type 2 diabetes. Two classes of drugs, GLP-1 receptor agonists and dipeptidyl peptidase inhibitors, provide comparable or superior glycemic effects to previous antidiabetic agents without increasing side effects, such as weight gain and hypoglycemia. Therefore, they represent valuable additions to the current therapeutic options for type 2 diabetes. Springer Science+Business Media New York, 2013 GLP-1 nationallicence DPP-4 nationallicence GLP-1 receptor agonists nationallicence DPP-4 inhibitors nationallicence Incretin nationallicence Type 2 diabetes nationallicence Weight loss nationallicence Hypoglycemia nationallicence Cardiovascular risk factors nationallicence Eckerle Mize Dara Division of Diabetes, Endocrinology, and Metabolism, Vanderbilt University Medical Center, 37232, Nashville, TN, USA aut Salehi Marzieh Department of Internal Medicine, Division of Endocrinology and Metabolism, University of Cincinnati, 45267, Cincinnati, OH, USA aut Current Diabetes Reports Current Science Inc. 13/3(2013-06-01), 307-318 1534-4827 13:3<307 2013 13 11892 https://doi.org/10.1007/s11892-013-0377-9 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11892-013-0377-9 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Eckerle Mize Dara Division of Diabetes, Endocrinology, and Metabolism, Vanderbilt University Medical Center, 37232, Nashville, TN, USA aut NATIONALLICENCE 700 1- Salehi Marzieh Department of Internal Medicine, Division of Endocrinology and Metabolism, University of Cincinnati, 45267, Cincinnati, OH, USA aut NATIONALLICENCE 773 0- Current Diabetes Reports Current Science Inc 13/3(2013-06-01), 307-318 1534-4827 13:3<307 2013 13 11892 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer